

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



微創醫療科學有限公司\*

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 00853)**

**APPOINTMENT OF ROTATING CO-CHIEF EXECUTIVE OFFICER  
AND OTHER SENIOR POSITIONS; AND  
GRANT OF SHARE OPTIONS**

**APPOINTMENT OF ROTATING CO-CHIEF EXECUTIVE OFFICER**

The board of directors (the “**Directors**” and the “**Board**”, respectively) of MicroPort Scientific Corporation (the “**Company**”, and together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. Jonathan W Chen (“**Mr. Chen**”) has been appointed as the Rotating Co-chief Executive Officer of the Company with effect from 27 June 2025, subject to rotation on a yearly basis and adjustment based on his performance. The setup of the office of a rotating co-chief executive officer aims at (i) strengthening the Group’s internationalisation, professionalisation, and the development of a young management talent pipeline, thereby injecting new momentum into the Company’s strategic execution and sustainable growth; and (ii) further enhancing the Group’s global corporate governance standards, comprehensively improving its international and professional operational capabilities, and substantively expanding the Group’s development footprint overseas.

The biographical details of Mr. Chen are set out as follows:

Mr. Chen, born in 1975, is the Chief International Business Officer of the Company, the chairperson of InterContinental CRM Committee of the Company and the co-chairperson of InterContinental Orthopedics Committee of the Company.

Mr. Chen has over 28 years of experience in the medical devices industry. Mr. Chen joined the Group in July 2012 and currently serves as its chief international business officer since June 2021, primarily responsible for the international business of the Group. He has served as a director and chairperson of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (a company listed on the Science and Technology Innovation Board Market of the Shanghai Stock Exchange with stock code: 688016 and being a subsidiary of the Company) since November 2023. Mr. Chen is also currently holding directorships in certain subsidiaries of the Group.

Prior to joining the Group, from June 1997 to July 2005, Mr. Chen was a health care investment banker covering life sciences companies for Alex Brawn & Sons, Deutsche Bank and Credit Suisse. From September 2005 to January 2011, Mr. Chen successively served as the vice president and senior vice president of business development and financial strategy at Angiotech Pharmaceuticals, Inc.

Mr. Chen obtained both of his bachelor's degree with honors in biological sciences and his bachelor's degree in economics from Stanford University in the United States in June 1997.

Mr. Chen is interested in 5,637,360 shares/underlying shares of the Company, representing approximately 0.3% of the issued share capital of the Company as at the date of this announcement. Save as disclosed, Mr. Chen is not interested or deemed to be interested in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Mr. Chen will hold office of a rotating co-chief executive officer of the Company with effect from 27 June 2025, subject to rotation on a yearly basis and adjustment based on his performance. He is not entitled to any emolument for serving as a rotating co-chief executive officer of the Company but is entitled to receive discretionary award shares, options and/or annual bonus as may be determined by the Board.

Save as disclosed above, as at the date of this announcement, Mr. Chen has not held any directorship in other listed public companies in Hong Kong or overseas in the last three years, and he is not related to any Directors, senior management, other substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) of the Company, nor does he hold any other positions with the Company or any of its subsidiaries.

Save as disclosed above, as at the date of this announcement, there is no other information which is discloseable nor is Mr. Chen involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning the appointment of Mr. Chen that need to be brought to the attention of the shareholders of the Company.

## **APPOINTMENT OF CHIEF MEDICAL OFFICER**

The Board is pleased to announce that Dr. Brian Yale Chang (“**Dr. Brian Chang**”) has been appointed as the Chief Medical Officer of the Company with effect from 27 June 2025.

Dr. Brian Chang will be primarily responsible for:

- (i) developing and overseeing medical affairs strategies across all therapeutics areas of the Group;
- (ii) providing expert medical insights, scientific guidance, medical review, and training across the Group's global operations;

- (iii) leading the Group's medical affairs team and collaborating closely with its commercial and market access functions to generate compelling clinical evidence in support of optimal patient access to the Group's medical devices;
- (iv) overseeing all medical and clinical development initiatives, while bridging clinical research, regulatory affairs, and commercial operations to ensure the safe and effective use of the Group's products;
- (v) designing medical education programs, supporting product launches with scientific data, and ensuring compliance with all applicable regulatory and ethical standards; and
- (vi) building out the Group's medical affairs capabilities and managing other related operations in the United States.

The office of the Chief Medical Officer will play a central role in shaping and executing a unified global medical affairs strategy through active engagement with both internal and external stakeholders.

The biographical details of Dr. Brian Chang are set out as follows:

Dr. Brian Chang, born in 1992 and the son of Dr. Zhaohua Chang, is an engineer and physician-scientist by training. He holds a Bachelor and Master of Science in Mechanical Engineering from Carnegie Mellon University, graduating with University Honors and a minor in Biomedical Engineering. He earned a Ph.D. in Medical Engineering and Medical Physics from the Massachusetts Institute of Technology (MIT) and a Doctor of Medicine (M.D.) from Harvard Medical School, graduating *magna cum laude*. He completed his residency in Internal Medicine at Massachusetts General Hospital through the Stanbury Physician-Scientist Program.

Dr. Brian Chang has served as a medical technology consultant to the Group since May 2020, contributing to technical due diligence, U.S. market entry strategy, and innovation-driven development efforts. He is the co-founder of several medical technology startups, including X-COR Therapeutics and InFlo Medical, where he has led early-stage research and development.

Previously, Dr. Brian Chang held a postdoctoral and lecturer appointment at MIT, where he oversaw interdisciplinary research teams and developed curriculum in cardiovascular physiology and medical technology. His academic research has focused on cardiac support devices and extracorporeal systems.

He has authored 14 peer-reviewed publications and is a named inventor on multiple U.S. patents related to cardiovascular and extracorporeal technologies. Dr. Brian Chang's contributions have been recognized through numerous honors, including the Paul & Daisy Soros Fellowship, the Seidman Prize for Outstanding Thesis, and teaching awards from both Harvard Medical School and MIT.

Dr. Brian Chang is entitled to receive discretionary award shares, options and/or annual bonus as may be determined by the Board.

## APPOINTMENT OF CHIEF OVERSEAS OPERATING OFFICER

In order to closely work with the executive leadership team to shape and implement a robust overseas business supporting strategy including but not limited to market access, quality assurance, regulatory affairs and supply chain functions, the Board is also pleased to announce that Mr. Benoit Clinchamps (“**Mr. Clinchamps**”) has recently been appointed as the Chief Overseas Operating Officer of the Company. Mr. Clinchamps will be primarily responsible for, including but not limited to, (i) building a consistent quality assurance mechanism and system for overseas business of the Group; (ii) creating systematic quality assurance training curriculum in overseas markets; (iii) strategically forming market access and regulatory affairs/clinical pathway for CE and FDA for new products of the Group; (iv) coaching and guiding local regulatory affair team in China on overseas initiative.

Mr. Clinchamps served as president of MicroPort CRM from May 2018 to November 2024. He has over 25 years of experience in the medical technology industry, and has successively served as vice president of quality assurance & regulatory affairs, vice-president of product development & regulatory affairs in Sorin group. Mr. Clinchamps holds an Engineering Degree from ICAM Lille France (Institut Catholique des Arts et Métiers). He furthermore completed a Management Course in Aerospace in ENSAE Toulouse France (Ecole Nationale Supérieure de l’Aéronautique et de l’Espace) and in TUM Germany (Technische Universität München). He is a certified 6 Sigma Black Belt and also took an Executive Course at INSEAD Fontainebleau France.

Mr. Clinchamps is entitled to receive discretionary award shares, options and/or annual bonus as may be determined by the Board.

The Board warmly welcomes Mr. Chen, Dr. Brian Chang and Mr. Clinchamps to their new roles and looks forward to their continued contributions to the Company’s innovation and global growth.

## GRANT OF SHARE OPTION

This section is made pursuant to Rule 17.06A, Rule 17.06B and 17.06C of the Listing Rules.

To provide incentives to Dr. Brian Chang and Mr. Clinchamps for their contributions to the Group and to attract and retain them for the continuous operations and developments of the Group, the Board has granted an aggregate of 3,700,000 share options (the “**Share Option(s)**”) under the share scheme adopted by the Company on 19 June 2023 (the “**Share Scheme**”) to Dr. Brian Chang and Mr. Clinchamps (the “**Grantees**”), who are eligible participants for the purpose of the Share Scheme (the “**Employee Participants**”), subject to the acceptance of the Share Options by the Grantees, to subscribe for up to an aggregate of 3,700,000 ordinary shares of the Company (the “**Shares**”) of US\$0.00001 each, representing approximately 0.20% of the issued share capital of the Company as at the date of this announcement, out of which, (i) Dr. Brian Chang was granted 3,500,000 Share Options, representing approximately 0.19% of the issued share capital of the Company; and (ii) Mr. Clinchamps was granted 200,000 Share Options, representing approximately 0.01% of the issued share capital of the Company.

## Details of the Share Options granted

|  |  |
|--|--|
| Date of grant:   | 27 June 2025   |
| Number of the Share Options granted:   | An aggregate of 3,700,000 Share Options, each Share Option entitling the holder to subscribe for one Share at the exercise price   |
| Exercise price of the Share Options granted:   | HK\$8.61 per Share   |
| Closing price of the Shares on the date of grant:  | HK\$8.61 per Share   |
| The average closing price of the Shares for the five trading days immediately preceding the date of grant: | HK\$8.334 per Share  |
| Validity period of the Share Options:  | Ten (10) years from the date of grant, i.e. from 27 June 2025 to 26 June 2035  |
| Consideration for the grant:   | HK\$1.00 to be paid by the Grantees upon acceptance of the Share Options granted   |
| Performance target   | <p>There is no performance target attached to the Share Options granted.</p> <p>The purpose of the Share Scheme is to provide incentive to the eligible participants in order to promote the development and success of the business of the Group. The Share Options granted to the Grantees are awarded to them based on their work performance, historical and potential contributions and thus no additional performance target is imposed before the Share Options are vested to the Grantees. In view of the above, the remuneration committee of the Company considered the grant of Share Options aligned with the purpose of the Share Scheme.</p> |
| Clawback mechanism:  | The Share Options granted were subject to the clawback mechanism as set out in the terms of the Share Scheme, including but not limited to the lapse of the Share Options upon cessation of employment of the Grantees.  |
| Financial assistance:  | There is no arrangement for the Group to provide any financial assistance to the Grantees to facilitate the purchase of Shares under the Share Scheme.   |

## VESTING CONDITIONS

Employee Participants: 3,700,000 Share Options granted shall vest and become exercisable in equal installments on each of the first five anniversaries of the date of grant.

## NUMBER OF SHARES AVAILABLE FOR FUTURE GRANT

After the above grant of Awards, 145,433,093 remaining Shares will be available for future grant under the existing scheme mandate limit of the Share Scheme, and 34,885,287 remaining Shares will be available for future grant under the service provider sublimit under the Share Scheme.

By Order of the Board  
**MicroPort Scientific Corporation**  
**Dr. Zhaohua Chang**  
*Chairman*

Shanghai, the People's Republic of China, 27 June 2025

*As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida and Ms. Weiqin Sun; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.*

\* *for identification purpose only*